The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer [0.03%]
人乳头瘤病毒循环肿瘤DNA在咽癌中的作用
Samuel N Regan,Michelle L Mierzwa
Samuel N Regan
Human papillomavirus infection is currently implicated in the majority of oropharyngeal squamous cell carcinoma cases diagnosed in the United States. Circulating tumor DNA (ctDNA) has emerged as a potential biomarker for human papillomaviru...
Andi K Cani,Simpa S Salami
Andi K Cani
The advent of high-throughput technologies has enabled the analysis of minute amounts of tumor-derived material purified from body fluids, termed "liquid biopsies." Prostate cancer (PCa) management, like in many other cancer types, has bene...
Circulating Tumor DNA in Human Papillomavirus-Mediated Oropharynx Cancer: Leveraging Early Data to Inform Future Directions [0.03%]
人乳头瘤病毒介导的口咽癌的循环肿瘤DNA:利用早期数据来指导未来研究方向
Molly E Heft Neal,Heather M Walline,Catherine T Haring
Molly E Heft Neal
Circulating tumor DNA (ctDNA) has become an area of intense study in many solid malignancies including head and neck cancer. This is of particular interest for human papillomavirus-mediated oropharyngeal squamous cell carcinoma as this coho...
Survival of the Fittest: How Adaptive Medicine Can Enhance Cancer Treatment [0.03%]
优胜劣汰:适应性医学如何增强癌症治疗
J Chad Brenner
J Chad Brenner
Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms [0.03%]
低恶性骨髓肿瘤治疗效益评判标准的变迁
Jessica M Stempel,Zhuoer Xie,Jan Philipp Bewersdorf et al.
Jessica M Stempel et al.
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disea...
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment [0.03%]
骨髓增生异常综合症治疗的新方法和未来方向
Jan Philipp Bewersdorf,Zhuoer Xie,Amer M Zeidan
Jan Philipp Bewersdorf
Myelodysplastic syndromes/neoplasms (MDSs) constitute a heterogeneous group of clonal disorders that are clinically characterized by dysplastic changes in multiple hematopoietic lineages, cytopenias, and a variable risk of progression to ac...
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in? [0.03%]
新型低甲基化剂在骨髓增生异常综合征治疗中的应用:维奈托克和异柠檬酸脱氢酶抑制剂如何定位?
Yasmin Abaza,Anand Ashwin Patel
Yasmin Abaza
Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders with treatment approaches tailored to the presence of cytopenias, disease risk, and molecular mutation profile. In higher-risk MDSs, the ...
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions [0.03%]
骨髓增生异常综合征的造血干细胞移植:现状与未来方向
Jean Sabile,Steven Pavletic,Yazan Migdady
Jean Sabile
Myelodysplastic syndromes (MDSs) are characterized by a clonal proliferation of hematopoietic stem cells with potential life-threatening cytopenia(s) and transformation to acute myeloid leukemia. Individualized risk stratification is evolvi...
Jessica M Stempel,Nikolai A Podoltsev,Talib Dosani
Jessica M Stempel
Myelodysplastic syndromes are a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis, progressive cytopenias, and an innate capability of progressing to acute myeloid leukemia. The most common causes of mo...
Abhay Singh,Hetty E Carraway
Abhay Singh
Myelodysplastic syndromes or myelodysplastic neoplasms (both abbreviated MDSs) (Leukemia 2022;36:1703-1719) have historically been challenging diseases to treat owing to their complex biology, molecular diversity, and a patient population t...